Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
202 Citations•2022•
Wissam Ghusn, Alan De la Rosa, Daniel Sacoto
Semaglutide treatment in a regular clinical setting was associated with weight loss similar to that seen in randomized clinical trials, which suggests its applicability for treating patients with overweight or obesity.
Abstract
The results of this cohort study suggest that weekly 1.7-mg and 2.4-mg doses of semaglutide were associated with weight loss similar to that seen in randomized clinical trials. Studies with longer periods of follow-up are needed to evaluate prolonged weight loss outcomes.